Etomoxir sodium salt [828934-41-4]
Cat# T4535-10mg
Size : 10mg
Marca : TargetMol
Etomoxir sodium salt
(Synonyms: (R)-Etomoxir sodium salt) Copy Product Info
Etomoxir sodium salt ((R)-Etomoxir sodium salt) is a carnitine palmitoyltransferase 1a (CPT-1a) inhibitor that inhibits fatty acid oxidation (FAO). Etomoxir sodium salt has antitumor activity.
Cas No. 828934-41-4
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.82%
Color:White
COA HNMR HPLC
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Etomoxir sodium salt ((R)-Etomoxir sodium salt) is a carnitine palmitoyltransferase 1a (CPT-1a) inhibitor that inhibits fatty acid oxidation (FAO). Etomoxir sodium salt has antitumor activity. |
| Targets & IC50 | Hepatocyte cells (rat):10 µM (fatty acid oxidation), faTT cellsy acid oxidation in Hepatocyte cells (guinea pig):1 µM, faTT cellsy acid oxidation in Hepatocyte cells (human):0.1 µM, KB cells:2.76 µM |
| In vitro | METHODS: BCa cell lines UM-UC-3 and T24 were treated with Etomoxir sodium salt (20-200 μM) for 24-72 h. Cell viability was examined using MTT. RESULTS: Etomoxir inhibited the viability of UM-UC-3 and T24 cells in a dose-dependent manner. [1] METHODS: Human breast cancer cells MCF-7 and T47D were treated with Etomoxir sodium salt (0.1-50 μM) for 24 h. Cellular FAO activity was measured by 3H palmitic acid. RESULTS: Low micromolar concentrations of Etomoxir were sufficient to achieve maximal inhibition of FAO in MCF-7 and T47D cells. [2] |
| In vivo | METHODS: To test the antitumor activity in vivo, Etomoxir sodium salt (40 mg/kg) was intraperitoneally injected into BALB/c nude mice carrying human bladder cancer tumor T24 every two days for twenty days. RESULTS: Etomoxir significantly inhibited tumor growth. [1] METHODS: To test the activity against multiple sclerosis, Etomoxir sodium salt (15 mg/kg) was intraperitoneally injected into a C57BL/6J mouse model of EAE induction once a week or every two days for two weeks. RESULTS: Etomoxir-treated mice showed reduced disease severity as well as reduced inflammation and demyelination. Disruption of fatty acid metabolism promotes downregulation of CNS inflammation and this metabolic pathway is a potential therapeutic target for multiple sclerosis. [3] |
| Synonyms | (R)-Etomoxir sodium salt |
| Molecular Weight | 320.74 |
| Formula | C15H18ClO4.Na |
| Cas No. | 828934-41-4 |
| Smiles | [Na+].[O-]C(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1 |
| Relative Density. | no data available |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 3.21 mg/mL (10.01 mM), Sonication is recommended.  H2O: 5 mg/mL (15.59 mM), Sonication is recommended. | ||||||||||||||||||||
| In Vivo Formulation | Saline: 3.5 mg/mL (10.91 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO/H2O
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||